USA Health Homepage

Navigation

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

Status: open

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

Treatment for Solid Tumors, Lymphomas, or Multiple Myeloma

Contact Us Or call (251) 445-9834

Description

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Sponsors

This trial is sponsored by National Cancer Institute (NCI).
Learn More at ClinicalTrials.gov

Location

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, AL 36604
(251) 665-8000

Providers Associated With This Trial

Principle Investigator

  • Rocconi RodneyView Profile
    Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistInterim Director of Mitchell Cancer Institute; Chief of Gynecologic Oncology Service; Associate Director for Clinical Research, Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical Oncology

Sub Investigators

This link will open in a new tab or window.